Modification Of Neutrophil Function By Plasma Of Rheumatoid Arthritis Patients Treated With Infliximab

Dain, Lena; Braun‐Moscovici, Yolanda; Nahir, A. M.; Baum, Elena; Hoffer, Erica

doi:10.1097/00007691-200504000-00060

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In RA, the systemic levels of cytokine released by subclinical synovitis in small joints do not reflect cytokine concentration in synovium, explaining, at least partly, that the time-integrated levels of IL-6 are uncoupled from radiologic progression. Moreover, IL-6 is rapidly and dramatically decreased by RA pharmaceutical treatments (26). Hence, the dependence of IL-6 levels on treatment is likely to explain why IL-6 was not an independent factor of structural progression in our multivariable analysis.…”

Section: Discussionmentioning

confidence: 89%

Evaluation of Serum Interleukin‐6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort

Baillet¹,

Gossec

Paternotte

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. Interleukin-6 (IL-6) is a key cytokine in rheumatoid arthritis pathogenesis. We aimed to analyze the association between IL-6 serum levels and joint inflammation at baseline and the correlation of time-integrated IL-6 values with structural damage during the first 36 months of early arthritis. Methods. IL-6 was assessed by 2 different methods in 813 patients of the French early arthritis cohort ESPOIR (Etude et Suivi des Polyarthrites Indiff erenci ees R ecentes) over 36 months. IL-6 and C-reactive protein (CRP) changes were correlated to radiographic progression assessed by the total Sharp/van der Heijde score (SHS). Synovium inflammation was assessed in a subgroup of 126 patients by ultrasonography (US). The relationship between SHS change and IL-6 or CRP levels at baseline was investigated by a univariate regression and a multivariable analysis. A longitudinal model nested by visit and patient was conducted to assess the role of IL-6 on SHS at each visit. Results. At baseline, IL-6 was more strongly correlated with the swollen joint count than CRP level. In the univariate analysis, the time-integrated value of IL-6 was more strongly correlated with the swollen joint count and the variation of SHS than timeintegrated CRP level. Baseline IL-6 was not independently associated with SHS change. Longitudinal models nested by patient showed that IL-6 levels were associated with structural damage independently from the Disease Activity Score in 28 joints, smoking status, rheumatoid factor, and anti-citrullinated protein peptide antibody serology, treatments, and CRP levels. Conclusion. IL-6 level was a marker of US synovitis at baseline. Repeated measurements of IL-6 are associated with structural damage.

show abstract

Section: Discussionmentioning

confidence: 89%

Evaluation of Serum Interleukin‐6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort

Baillet¹,

Gossec

Paternotte

et al. 2015

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

“…IFX is also reported to induce a rapid and marked reduction in circulating interleukin 6 (IL-6) levels, suggesting that its efficacy may result from the suppression of IL-6 as well as TNF 2–5. In the RISING Study (NCT00691028),6 7 we observed patients who showed no response to IFX therapy, despite maintaining a serum IFX level higher than the threshold level for clinical response.…”

mentioning

confidence: 89%

Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study

Takeuchi

Miyasaka

Tatsuki³

et al. 2012

Ann Rheum Dis

View full text Add to dashboard Cite

“…SSRI use is known to decrease serum IL-6 in depressed patients (21). Some reports also state that the use of infliximab lowers serum TNF-α, IL-6, and dehydroepiandrosterone-sulfate (DHEA-S), which is a hormone related to the depressive state (22,(24)(25)(26). In this study, we did not measure TNF-α, IL-6, or DHEA-S, but their levels may provide data that will help clarify the cause of the depressive state and improve the depressive state of rheumatoid arthritis patients using drug therapy.…”

Section: Discussionmentioning

confidence: 99%

Combined infliximab and methotrexate treatment improves the depressive state in rheumatoid arthritis patients more effectively than methotrexate alone

Miwa

Nishimi

et al. 2014

Eur J Rheumatol

View full text Add to dashboard Cite

Combined infliximab and methotrexate treatment improves the depressive state in rheumatoid arthritis patients more effectively than methotrexate alone Abstract Objective: Rheumatoid arthritis (RA) patients have a greater depressive tendency than normal subjects, and infliximab is known to provide quick therapeutic effects and to have high bioavailability for RA. We therefore investigated whether the depressive state of RA patients would be improved by infliximab.Material and Methods: The Self-Rating Depression Scale (SDS) was used to evaluate 34 RA patients before and 14 or 30 weeks after inflixi mab treatment using the SDS and Disease Activity Score (DAS) 28. The SDS and DAS28 results before and after treatment were compared. Results:We also included 42 cases treated with methotrexate as the control group. The SDS decreased in both groups, and the intraindividual vari ability was p<0.001, indicating that the drugs had significantly different effects on the SDS. The DAS tended to decrease in both groups, but the intraindividual variability was p=0.199, indicating no difference between the two drugs. Conclusion:This study is a preliminary study, but the data suggest that infliximab may reduce RA disease activity and improve the depressive state.

show abstract

Modification Of Neutrophil Function By Plasma Of Rheumatoid Arthritis Patients Treated With Infliximab

Cited by 7 publications

References 0 publications

Evaluation of Serum Interleukin‐6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort

Evaluation of Serum Interleukin‐6 Level as a Surrogate Marker of Synovial Inflammation and as a Factor of Structural Progression in Early Rheumatoid Arthritis: Results From a French National Multicenter Cohort

Inhibition of plasma IL-6 in addition to maintenance of an efficacious trough level of infliximab associated with clinical remission in patients with rheumatoid arthritis: analysis of the RISING Study

Combined infliximab and methotrexate treatment improves the depressive state in rheumatoid arthritis patients more effectively than methotrexate alone

Contact Info

Product

Resources

About